Third Harmonic Bio Inc.

Third Harmonic Bio — Investor Presentation (October 2022)

20 slides from Third Harmonic Bio's investor presentation, Oct 11, 2022

  1. Slide 1: Advancing the Next Wave of Medicine for Allergy and Inflammation

    Advancing the Next Wave of Medicine for Allergy and Inflammation ©2022 THIRD HARMONIC BIO OCTOBER 2022 Exhibit 99.1

  2. Slide 2: Forward Looking Statements

    Forward Looking Statements This presentation contains forward-looking statements within the meaning of, and made pursuant to the safe harbor provisions of, the Private Securities Litigation Reform Act of 1995. Any statements made in this presentation that are not statements of historical fact, inclu

  3. Slide 3: Pipeline-in-a-Product Potential: THB001 Selective Oral KIT Inhibitor

    “Pipeline-in-a-Product” Potential THB001: Selective Oral KIT Inhibitor KIT: A Novel, Clinically Validated Target Large Established Markets With High Unmet Need Third Harmonic Bio: clinical-stage company with oral wild-type KIT inhibitor to treat mast cell-mediated diseases Millions of patients livin

  4. Slide 4: Mast Cells are a Fulcrum of Allergy and Inflammation

    Receptor-binding agonists IgE Complement Neuropeptides Microbial products Cytokines TSLP Chemokines Physical activators Temperature Pressure Cell-cell contact Pre-formed Mediators Histamine IL-4, IL-13 TNF, GM-CSF Proteases Serotonin Heparin Newly Synthesized Mediators Prostaglandins Leukotrienes Cy

  5. Slide 5: Chronic Urticaria Disease Overview

    Prevalence: More than 1.5 million patients or 0.5-1% point prevalence; ~70-80% female, mean age ~46 years Symptoms: severely itchy, painful wheals and angioedema which confer significant mental health and quality of life burdens Etiology: both inducible (caused by specific stimuli/triggers) and spon

  6. Slide 6: Severe Asthma Disease Overview

    Severe Asthma Disease Overview Limited oral treatment options for patients beyond corticosteroids and anti-leukotrienes Prevalence: ~5-10% of all asthma patients; estimated 750K – 1 million patients in US; adult population ~60% female, mean age ~50 years Definition: disease not sufficiently controll

  7. Slide 7: Targeting KIT Has Been Shown To Broadly Inhibit Mast Cell Activity

    Targeting KIT Has Been Shown To Broadly Inhibit Mast Cell Activity Demonstrated clinical efficacy in chronic spontaneous urticaria Master regulator of mast cell proliferation, migration, activation and survival Inhibition of KIT drives both mast cell inactivation and depletion KIT (CD117) Barzovolim

  8. Slide 8: THB001: Highly Selective Oral Wild-Type KIT Inhibitor

    THB001: Highly Selective Oral Wild-Type KIT Inhibitor Potent KIT inhibitor High kinome selectivity Depleted mast cells in relevant GI, skin and lung tissues of rats and dogs Demonstrated efficacy in rat models of dermal anaphylaxis and asthma Favorable pharmacokinetic profile including high oral bio

  9. Slide 9: Phase 1a Trial Design

    Phase 1a Trial Design THB001: Phase 1 SAD/MAD/Food Effect in Healthy Volunteers Single Ascending Dose (n=42) Healthy Male/Female, 18-65 yrs Plasma PK 300mg 600mg 400mg FED 30mg 100mg 10mg Multiple Ascending Dose x 14 Days (n=32) Healthy Vasectomized Male/Female 18-65 yrs Plasma/Urine PK Pharmacodyna

  10. Slide 10: THB001 PK Summary: Unbound Trough Values vs KIT Cellular IC50

    Unbound THB001 Trough Values vs KIT Cellular IC50 200mg QD: ~1.5-2-fold 200mg BID: ~10-fold 500mg QD FED: ~10-fold 400mg BID: ~20-fold Mean t1/2 ~24 hours THB001 Multiple Dose PK (14 days) Study Day [Trough Plasma THB001](ng/mL) KIT cellular IC50 1 200mg QD 200mg BID 400mg BID 500mg QD FED End of tr

  11. Slide 11: THB001 Phase 1a Adverse Events Summary

    THB001 200mg QD 200mg BID 500mg QD FED 400mg BID PBO Preferred Term, n % 6 % of (n) 6 % of (n) 6 % of (n) 6 % of (n) 8 % of (n) Hair Color Changes 2 33.3% 6 100.0% 4 66.7% 5 83.3% — — Headache 2 33.3% 2 33.3% 4 66.7% 2 33.3% 3 37.5% Nausea 1 16.7% 2 33.3% 2 33.3% — — 2 25.0% Diarrhea 1 16.7% 1 16.7%

  12. Slide 12: THB001 Hematology – Mean Neutrophil Count

    THB001 Hematology – Mean Neutrophil Count (+/- SD) Placebo multiple dose 200mg THB001 multiple dose QD 200mg THB001 multiple dose Q12H 400mg THB001 multiple dose Q12H 500mg THB001 multiple dose QD FED ULN LLN ULN=upper limit of normal; LLN=lower limit of normal Mean ± SD Study Day Neutrophils (109/L

  13. Slide 13: Hematology Parameter Comparison – THB001 and Barzovolimab in NHVs

    Hematology Parameter Comparison –THB001 and Barzovolimab in NHVs THB001 200mg QD 200mg BID 400mg BID 500mg QD FED PBO Leukocytes (109/L) - WBC -0.6 (1.2) -0.7 (1.3) -1.9 (1.0) -1.3 (1.4) -0.5 (0.6) Erythrocytes (1012/L) - RBC -0.3 (0.3) -0.3 (0.2) -0.5 (0.1) -0.4 (0.3) -0.04 (0.2) Hematocrit (%) -0.

  14. Slide 14: THB001 PD Summary: Serum Tryptase

    THB001 PD Summary: Serum Tryptase Serum Tryptase Normalized to Baseline Over Time LLOQ PBO 200mg QD 200mg BID 400mg BID 500mg QD FED PBO 400mg BID LLOQ=lower limit of quantitation; Mean ± SD PBO = placebo Serum Tryptase (% Baseline) Study Day End of treatment Mean Absolute Serum Tryptase Over Time S

  15. Slide 15: Phase 1b Chronic Inducible Urticaria Study Design

    Phase 1b Chronic Inducible Urticaria (CIndU) Study Design Design Open label, dose escalation design 3 doses (1:1:1) of THB001 (total N=30) for 12 weeks on treatment Generally healthy male and female patients aged 18-75 with Dx’d Cold Induced Urticaria Objectives Safety and Tolerability Mean reductio

  16. Slide 16: THB001·HCl salt outperforms free base in NHV bio-comparison study

    THB001·HCl salt outperforms free base in NHV bio-comparison study Significant increase in exposure with THB001 salt Favorable PK profile Supports potential for QD dosing Manufacturing underway to introduce into upcoming clinical studies – no additional tox/clinical requirements to support transition

  17. Slide 17: Indication Expansion: Severe Asthma

    Indication Expansion: Severe Asthma Moderately potent KIT inhibitor 43% reduction in serum tryptase --> significant improvements in FEV1 and airway hyperreactivity Non-endotype restricted study population Provides human PoC, even with suboptimal KIT inhibition Cahill, et al., NEJM, May 2017 Gleevec

  18. Slide 18: Phase 1b Inducible Allergic Asthma POC Trial Concept Design

    Phase 1b Inducible Allergic Asthma POC Trial Concept Design Design Summary Study Design: Parallel, Blinded, PBO controlled, 2-3 THB001 doses + PBO (1:1:1): N=~10-15/arm Patient Population: mild, stable allergic asthmatic subjects, not on regular anti-inflammatory treatment Primary Endpoint: change f

  19. Slide 19: Anticipated Milestones

    Anticipated Milestones ANTICIPATED MILESTONES Phase 2H’22 1H’23 2H’23 1H’24 2H’24 Chronic inducible urticaria Phase 1b Asthma Phase 1b Chronic spontaneous urticaria Phase 2 THB001: Multiple Upcoming Clinical Catalysts Trial initiation Data Readout Regulatory Submission2 Regulatory Submission1 Data R

  20. Slide 20: Advancing the Next Wave of Medicine for Allergy and Inflammation

    Advancing the Next Wave of Medicine for Allergy and Inflammation ©2022 THIRD HARMONIC BIO

Third Harmonic Bio — Investor Presentation (October 2022) on 6ix